Detalhe da pesquisa
1.
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance.
Nature
; 623(7989): 1053-1061, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37844613
2.
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
J Clin Invest
; 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38833311
3.
The potential role of the microbiota in prostate cancer pathogenesis and treatment.
Nat Rev Urol
; 20(12): 706-718, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37491512
4.
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
Eur Urol
; 83(3): 224-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36114082
5.
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.
Cancer Res
; 82(2): 221-234, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34625422
6.
Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.
Mol Cancer Ther
; 21(4): 594-606, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35086954
7.
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours.
Eur J Cancer
; 162: 209-220, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34933802
8.
The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas.
Cancer Genomics Proteomics
; 17(6): 715-727, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33099473
9.
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].
Eur Urol
; 83(6): e168-e169, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964041